Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P488: Efficacy of pre-operative oral antibiotic prophylaxis for the prevention of wound infections in patients with Crohn's diseaseECCO '18 Vienna
Year: 2018
Authors:

M. Uchino*, H. Ikeuchi, T. Bando, T. Chohno, H. Sasaki, Y. Horio, R. Kuwahara, T. MInagawa

Hyogo College of Medicine, Inflammatory Bowel Disease, Nishinomiya, Japan

P489: Clinical experience with ustekinumab in selected Crohn's disease patientsECCO '18 Vienna
Year: 2018
Authors:

S. Saman*, T. Klag, J. Wendler, M. Goetz, N.P. Malek, J. Wehkamp

University Hospital Tuebingen, Gastroenterology, Tuebingen, Germany

P490: Drug survival and immunogenicity after switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: Two-year follow-up of a prospective observational cohort studyECCO '18 Vienna
Year: 2018
Authors:

L. Smits1*, L. Derikx1,2, A. van Esch1, J. Drenth1, R. Boshuizen3, D. de Jong1, F. Hoentjen1

1Radboud University Medical Centre, Gastroenterology and Hepatology, Nijmegen, The Netherlands, 2Jeroen Bosch Hospital, Gastroenterology and Hepatology, Hertogenbosch, The Netherlands, 3Sanquin Diagnostic Services, Biologics Laboratory, Amsterdam, The Netherlands

P491: Comparative efficacy on mucosal healing of pharmacological therapies for moderate-to-severe ulcerative colitis, based on prior exposure to tumour necrosis factor antagonists: A systematic review and network meta-analysisECCO '18 Vienna
Year: 2018
Authors:

P. Paschos1,2, A. Katsoula3, O. Giouleme3*, A. Tsapas1,4

1Aristotle University, Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Thessaloniki, Greece, 2“Papageorgiou” Hospital, 1st Department of Internal Medicine, Thessaloniki, Greece, 3Aristotle University, Second Propedeutic Medical Department, Thessaloniki, Greece, 4University of Oxford, Harris Manchester College, Oxford, UK

P492: Gender differences in patient’s perspectives for impact of inflammatory bowel disease on their life: An Online Korean Association for the Study of Intestinal Disease (KASID) surveyECCO '18 Vienna
Year: 2018
Authors:

Y.S. Kim1*, G.S. Seo2, S.W. Hwang3, H.J. Yang4, C.H. Tae5, H.J. Lee6, D.-w.L. Lee7, Y.J. Lee8, D.-S. Myung9, J.M. Lee10, Y.T. Jeen11

1Seoul National University Hospital Gangnam Center, Internal Medicine, Seoul, South Korea, 2Wongkwang University Hospital, Internal Medicine, Iksan, South Korea, 3University of Ulsan College of Medicine, Internal Medicine, Seoul, South Korea, 4Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Internal Medicine, Seoul, South Korea, 5College of Medicine, Ewha Womans University, Internal Medicine, Seoul, South Korea, 6Seoul National University Hospital, Internal Medicine, Seoul, South Korea, 7Korea University Ansan Hospital, Internal Medicine, Ansan-si, South Korea, 8Keimyung University School of Medicine, Internal Medicine, Daegu, South Korea, 9Chonnam National University Medical School, Internal Medicine, Gwangju, South Korea, 10St. Vincent's Hospital, Internal Medicine, Suwon, South Korea, 11Korea University Hospital, Internal Medicine, Seoul, South Korea

P493: Comparison of the efficacy of infliximab biosimilar (Remsima®) vs. infliximab original (Remicade®) in patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

M.F. Guerra Veloz1*, M. Belvis Jimenez1, T. Valdes Delgado1, R. Perea Amarillo1, L. Castro Laria1, B. Maldonado Pérez1, V. Merino2, A. Benítez Roldán1, A. Caunedo Álvarez1, F. Argüelles-Arias1

1Virgen Macarena Hospital, Gastroenterology, Sevilla, Spain, 2Virgen Macarena Hospital, Pharmacy Unit, Sevilla, Spain

P494: Monocytic TNF production predicts response to infliximab treatment in Crohn’s disease but not ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

B. Jessen1,2*, D. Lissner1, E. Sonnenberg1, M. Schumann1, F. Schmidt1, A. Kühl1, B. Siegmund1

1Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Department for Medicine (Gastroenterology, Infectious diseases, Rheumatology), Berlin, Germany, 2Berlin Institute of Health, Berlin, Germany

P495: Does drug level monitoring help us to understand the mechanism behind the superiority of combo therapy in inflammatory bowel diseases?ECCO '18 Vienna
Year: 2018
Authors:

A. Fábián1*, K. Szántó1, A.L. Szíjártó2, R. Bor1, A. Bálint1, K. Farkas1, Á. Milassin1, M. Rutka1, Z. Szepes1, I. Földesi3, D. Kata3, Z.A. Mezei4, S. Lovas5, K. Palatka5, T. Molnár1

1University of Szeged, First Department of Medicine, Szeged, Hungary, 2University of Szeged, Department of Medical Physics and Informatics, Szeged, Hungary, 3Institute of Laboratory Medicine, Szeged, Hungary, 4University of Debrecen Clinical Center, Department of Laboratory Medicine, Debrecen, Hungary, 5University of Debrecen, 2nd Department of Internal Medicine, Debrecen, Hungary

P496: Real-world outcomes of vedolizumab for inflammatory bowel disease post liver transplantationECCO '18 Vienna
Year: 2018
Authors:

M. Peverelle*, C. Mills, A. Testro, P. de Cruz

Austin Health, Gastroenterology and Hepatology, Melbourne, Australia

P497: Injection site reactions and injection site pain for the adalimumab biosimilar ABP 501: Results from two double-blind, randomised, controlled studiesECCO '18 Vienna
Year: 2018
Authors:

E. Krishnan*, N. Zhang, H. Wang

Amgen Inc., Biosimilars, Thousand Oaks, USA

P498: Crohn’s disease patient’s isolated classical monocytes are characterised by reduced secretion of Wnt-ligands affecting Paneth cell antimicrobial host defenseECCO '18 Vienna
Year: 2018
Authors:

N.S. Armbruster*, U. Denzau-Graupner, T. Klag, M. Götz, N. Malek, J. Wehkamp

University Hospital Tübingen, Internal Medicine I, Tübingen, Germany

P499: A comparison of health-related quality of life in nurse-led vs. conventional inflammatory bowel disease follow-upECCO '18 Vienna
Year: 2018
Authors:

L. Alvestad1*, L.-P. Jelsness-Jørgensen2,3, R. Goll4, A. Clancy5, P.C. Valle6, A.R. Broderstad7

1UiT, The Arctic University of Norway, Department of Health and Care Sciences, Harstad, Norway, 2Østfold University College, Fredrikstad, Norway, Fredrikstad, Norway, 3Østfold Hospital Trust, Department of Gastroenterology, Kalnes, Norway, 4University Hospital of North Norway, UNN, Tromsø, Norway, 5UiT, The Arctic University of Norway, Department of Health and Care Sciences, Harstad, Norway, Harstad, Norway, 6University Hospital of North Norway, Harstad, Norway, 7UiT, The Arctic University of Norway, Harstad, Norway

P500: The effects of EBV naïve status on treatment decisions in patients with inflammatory bowel disease: Does the risk of GI lymphoma justify the cost?ECCO '18 Vienna
Year: 2018
Authors:

T. Ahmed1, F. Brown1, R. Ahmed1, S. Whitehead2, H. Steed1, M.J. Brookes1*

1Royal Wolverhampton NHS Trust, Gastroenterology Unit, Wolverhampton, UK, 2Royal Wolverhampton NHS Trust, Clinical Biochemistry Unit, Wolverhampton, UK

P501: Vedolizumab for UC after infliximab failure in PSC patients after OLTx: Two case reportsECCO '18 Vienna
Year: 2018
Authors:

P. Drastich*, J. Brezina, L. Bajer, M. Benes, J. Spicak

Institute of Clinical and Experimental Medicine, Hepatogastroenterology, Prague, Czech Republic

P502: Clinical and endoscopic features of secondary loss of response cases in patients with Crohn’s disease treated with infliximab by top-down strategy: A case–control studyECCO '18 Vienna
Year: 2018
Authors:

T. Miyazaki1*, A. Fujimori1, R. Koshiba1, K. Fujimoto1, T. Sato1, M. Kawai2, Y. Kita1, K. Kamikozuru1, T. Takagawa2, Y. Yokoyama1, N. Hida1, K. Watanabe2, S. Nakamura1

1Hyogo College of Medicine, Inflammatory Bowel Disease, Nishinomiya, Japan, 2Hyogo College of Medicine, Intestinal Inflammation Research, Nishinomiya, Japan

P503: Can daily SCCAI measurements over a 6-month period better phenotype the pattern of disease in ulcerative colitis?ECCO '18 Vienna
Year: 2018
Authors:

A. Walsh1*, A. Kormilitzin2, C. Hinds3, V. Sexton4, J. Wilson1, M. Peters5, O. Brain1, S. Keshav1, H. Uhlig1, J. Geddes4, G. Goodwin4, G. Collins6, S. Travis1

1John Radcliffe Hospital, Translational Gastroenterology Unit, Oxford, UK, 2Mathematical Institute, Oxford, UK, 3Big Data Institute, Oxford, UK, 4University of Oxford, Psychiatry Department, Oxford, UK, 5University of Oxford, Nuffield Department of Population Health, Oxford, UK, 6University of Oxford, Centre for Statistics in Medicine, Oxford, UK

P504: The variation of faecal calprotectin after 3 months of anti-TNF therapy is a predictor of sustained clinical remission in patients with Crohn's diseaseECCO '18 Vienna
Year: 2018
Authors:

E. Sollelis1,2*, R. Minet Quinard3, G. Bouguen4, M. Goutte1,2, F. Goutorbe1,5, D. Bouvier3, B. Pereira6, G. Bommelaer1,2, A. Buisson1,2

1University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France, 2UMR 1071 Inserm/Université d'Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the Host, Clermont-Ferrand, France, 3University Hospital G. Montpied, Biochemistry Laboratory, Clermont-Ferrand, France, 4University Hospital, Rennes, France, 5Hospital of Bayonne, Gastroenterology Department, Bayonne, France, 6University Hospital, Biostatistics Unit, DRCI Clermont-Ferrand, France

P505: Factors influencing outcomes from surgery for Crohn’s disease: A perspective from a district hospitalECCO '18 Vienna
Year: 2018
Authors:

A.R. Aspari*, N. Husain, P. Thomas

Burton Hospitals NHS Foundation Trust, Colorectal Surgery, Burton On Trent, UK

P506: Incidence risk of colorectal cancer, non-melanoma skin cancers and non-Hodgkin lymphoma in Japanese patients with ulcerative colitis based on large-scale claims databaseECCO '18 Vienna
Year: 2018
Authors:

T. Kobayashi1*, A. Uda2, T. Mineyama2, E. Udagawa2, K. Iwasaki3, W. Tang3, T. Hibi1

1Center for Advanced IBD Research and Treatment, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan, 2Takeda Pharmaceutical Company Limited, Tokyo, Japan, 3Milliman, Inc., Tokyo, Japan

P507: What is the impact of infliximab metaoptimisation on surgical rates and need-to-change-therapy in real-world practice for severe inflammatory bowel disease?ECCO '18 Vienna
Year: 2018
Authors:

T. Lefebvre1, R. Cormons1, J.-L. Faucheron2, M. Baudrant3, B. Bonaz1, N. Mathieu4*

1Grenoble Alpes University Hospital, University Clinic of Hepato-Gastroenterology, Grenoble, France, 2Grenoble Alpes University Hospital, Colorectal Unit Department of Surgery, Grenoble, France, 3Grenoble Alpes University Hospital, Department of Pharmacy, Grenoble, France, 4CHU Grenoble Alpes, University Clinic of Hepato-Gastroenterology, Grenoble, France